替罗非班注射液治疗进展性缺血性脑卒中的效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Tirofiban Injection in the treatment of progressive ischemic stroke (PIS).Methods A total of 82 patients with PIS admitted to Anshan Changda Hospital from February 2018 to February 2020 were selected and divided into a control group and a study group by random number table method,with 41 cases in each group.The control group received conventional treatment,and the study group received Tirofiban Injection on the basis of the control group.The treatment time was 48 hours and the treatment course was 2 weeks.The clinical efficacy,platelet function,National Institutes of Health Stroke scale (NIHSS) score,modified Rankin scale(mRS) score,inflammatory factors (interleukin-6 [IL-6],and hypersensitivity C-reactive protein [hs-CRP]) levels and bleeding events were compared between the two groups.Results The total effective rate of the study group was 95.12%,which was higher than that in the control group (80.49%),the difference was statistically significant (P＜0.05); the platelet aggregation rate,platelet adhesion rate,and CD62p of the study group were lower than those in the control group after treatment,the differences were statistically significant (P＜0.05); NIHSS score and mRS score of the study group after treatment were lower than those of the control group,the differences were statistically significant (P＜0.05);IL-6 and hs-CRP of the study group were lower than those in the control group after treatment,the differences were statistically significant (P＜0.05); the incidence of bleeding events in the study group was 9.76%,which was compared with that in the control group (4.88%),the difference was not statistically significant (P ＞0.05).Conclusion The application of Tirofiban injection is effective in PIS patients,and it is recommended to be further promoted.

Key words： Tirofiban Injection Progressive ischemic stroke Platelet function Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I5/9

[14]	孙原，石秋艳，李冬梅，等.替罗非班桥接治疗急性缺血性脑卒中阿替普酶溶栓后的疗效观察[J].中国煤炭工业医学杂志，2017，20（4）：391-395.
[15]	王伟丽.丁苯酞序贯治疗对急性进展性脑梗死患者的疗效神经功能及炎症因子表达的影响[J].实用医技杂志，2019，26（10）：1320-1321.
[16]	周涛，侯宇峰.血清炎症因子水平与进展性脑卒中的相关性分析[J].神经损伤与功能重建，2020，15（5）：293-295.
[17]	刘强，王永利，王征宇，等.动静脉联合灌注替罗非班在非大血管闭塞急性缺血性脑卒中患者中的应用[J].介入放射学杂志，2019，28（12）：1131-1135.
[18]	焦冬生，赵全钱，时德，等.替罗非班联合奥扎格雷纳治疗进展性脑卒中的临床疗效及其对血小板水平影响分析[J].贵州医药，2018，42（1）：39-41.
[19]	王毅，欧阳玥，康绍军，等.血清炎症因子在急性缺血性脑卒中后感染患者中的变化[J].检验医学与临床，2020，17（1）：54-57，61.
[3]	吕娟，王润青.替罗非班治疗进展性缺血性卒中的疗效和安全性观察[J].海峡药学，2018，20（8）：142-143.
[1]	Hu X，De Silva TM，Chen J，et al.Cerebral vascular disease and Neurovascular Injury in ischemic stroke[J].Circ Res，2017，120（3）：449-471.
[2]	Fluri F，Schuhmann MK，Kleinschnitz C.Animal models of ischemic stroke and their application in clinical research[J].Drug Des Devel Ther，2015，9（10）：3445-3454.
[4]	郝静，赵娜，孔孟丹，等.替罗非班治疗进展性缺血性卒中的疗效和安全性观察[J].解放军医学院学报，2017，38（5）：409-413.
[5]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[6]	Kwah LK，Diong J.National Institutes of Health Stroke Scale（NIHSS）[J].J Physiother，2014，60（1）：61.
[7]	谭宝慧，杨宏.降纤、抗凝、抗血小板聚集联合治疗进展性脑卒中疗效及安全性[D].长春：吉林大学，2007.
[8]	Sulter G，Steen C，De Keyser J.Use of the Barthel index and modified Rankin scale in acute stroke trials[J].Stroke，1999，30（8）：1538-1541.
[9]	李耀鹏，赵鑫，朱晓临.替罗非班治疗缺血性脑卒中的应用进展[J].卒中与神经疾病，2020，27（1）：127-132.
[10]	黄志宝，何忠莲，汤红薇，等.替罗非班联合丁苯酞注射液治疗进展性脑梗死[J].血栓与止血学，2018，24（1）：10-12.
[11]	马冬璞，肖茜茜，李菲菲，等.替罗非班治疗进展性脑梗死临床观察[J].中国实用神经疾病杂志，2020，23（7）：576-580.
[12]	李晓红，刘文栋.血栓通注射液联合氯吡格雷治疗进展性缺血性脑卒中的临床研究[J].中西医结合心脑血管病杂志，2018，16（7）：986-989.
[13]	张海奇，常万生，林峰，等.替罗非班联合双联抗血小板治疗进展性卒中的临床疗效及安全性[J].中国医师进修杂志，2020，43（5）：388-392.